Power

Every day, a clinical trial is delayed due to recruitment planning issues. Often, it’s because recruitment planning came too late in the process. Today, we’re excited to share our latest white paper, Blueprint for Modern Patient Recruitment, which consolidates the top strategies sponsors are using to effectively plan and execute patient recruitment. We explore: 👉 How to quantify ROI on patient recruitment investments 👉 Fundamental shifts from a traditional to modern recruitment approach 👉 5 strategies top sponsors are using to modernize patient recruitment 👉 How to build a culture of patient centricity For industry professionals aiming to drive change and create more certainty in clinical trial recruitment, this white paper is not just a must-read but a roadmap to success. #ClinicalResearch #PatientRecruitment #ClinicalTrials #ClinicalTrialDiversity https://bit.ly/3IjykSp

Last week at the CNS Summit, I had the privilege of moderating a panel on patient trust in psychiatry trials with Kevin Craig, Michael Gold and Dan Karlin. Here are the most important takeaways from our discussion 👇 #CNSSummit2024

It’s not every day you leave a conference feeling like the momentum is unstoppable—but that’s exactly how CNS Summit felt for us. 🚀 Seeing people get excited about the mission behind withpower.com was inspiring. 👕 If you didn't get a chance to grab a t-shirt, we'd love to send you one. 👉 https://lnkd.in/g5x8DaWK To everyone we met at CNS, thank you for the conversations and the inspiration. If we didn’t connect this time, I’d love to keep the dialogue going. Always fun to catch up with old friends and new! Dawn Brockett, AMIR KALALI, MD, Michelle Longmire, Lauren Sunshine, Emily Epstein, LMSW, Joe Dustin, Megan Kelly, Steven T. Szabo, MD, PhD, Jaskaran (Jaz) Singh, Jose Contreras, Heather Sutton, Kabir Nath, Srinivas Rao, Maggie Gordon, Alexandra Dosen, Leah Moore (Getchell), Atul Mahableshwarkar, Timo Taghizadeh, Hugo Vimal, Emily Scullin, Morgan Touey Rinnier, Jessica (Jess) Potestivo, Jennylyn Trainor, Katie Rodammer, M.H.A., Justin Goodarz, Mitchell Efros, Kelly Calistri, Karma Hamilton, Jessica Griffiths, Ni Khin, Leah Aluisio, Susanna Chang, Anthony Duong, Reuben F. #CNSSummit2024

"Clinical trial participants should be national heroes" Kevin Craig, Michael Gold and Dan Karlin joined me to discuss building patient trust in clinical trials at CNS Summit A few salient points stood out: 1. Trust in pharma is at an all time low. While we can't do anything about misaligned incentives, there is plenty that sponsors and sites can be intentional about. 2. It starts with honesty. Especially given the hype in psychedelic research, it's important to be clear about expectations. One site we spoke with has even transitioned to calling patients "volunteers". 3. Patient recruitment is the tip of the spear. This starts with response rates and flows through to how medical information is collected, shared, and protected 4. The site experience drives so much. First impressions at a clinic from the waiting room to staff organization can put patients at ease or on edge Had a blast moderating this panel and can't wait to reconnect with the CNS community next year

Less than 1 week until the CNS Summit! Next Tuesday, I’ll be moderating a conversation on patient trust in psychiatry trials. 🧠✨ Join us for the session "Beyond Transparency: Rethinking Patient Trust in Psychiatry Trials" on Tue, Nov 12 @ 2pm with a powerhouse panel: - Michael Gold, Chief R&D Officer at Compass Pathways - Dan Karlin, CMO at MindMed - Kevin Craig, SVP Clinical Development at atai Life Sciences We’ll be diving into what it takes to build trust with patients in psychiatry research and why this challenge is especially critical in the field of mental health and psychedelics. Expect thought-provoking insights on transparency, patient empowerment, and the future of patient engagement in psychiatry trials. Looking forward to seeing you there! #CNSSummit2024 #ClinicalTrials #PatientTrust

I had a great time on Power's podcast with Brandon Li, sharing insights on building high-performing neuropsych research sites and innovative Alzheimer's recruitment strategies. We discussed: Patient-first sites: Accessible clinics with remote capabilities and tech integration. Tech in trials: EMR tools for identifying candidates, virtual pre-screening, and reaching underserved communities. Recruitment challenges: Blending community outreach with technology and supporting caregivers. Key learnings: Compassion and education for patient retention and trial participation. What are your thoughts on using tech and patient-centered approaches in Alzheimer’s research? 👇 Full episode link in the comments!

Speed matters in patient recruitment...and more than you might think ⚡ We dug into the data, and it turns out that calling patient referrals within 5 hours boosts screening visit bookings by 50% compared to a 22-hour delay. Read more here 👇

🎙️This week, something new...we're talking about building high-performing sites in neuropsych. In this episode, Jessica Branning, President of JBran Consulting and former CEO of ClinCloud, discusses her journey building high-performing clinical research sites in the neuropsych space and the innovative approaches she's bringing to Alzheimer's recruitment. Here’s what we cover: 1. Building patient-first research sites - Creating accessible, patient-centric clinics with remote capabilities - Embracing tech like EMR-integrated recruitment tools - Offering assessments as part of continuity of care 2. Role of tech in Alzheimer’s trials - How EMR integrations can identify trial candidates - Remote pre-screening and virtual assessments for wider reach - Tech solutions to connect with underserved areas and diverse communities 3. Overcoming patient recruitment challenges - Combining community engagement with tech innovations - Tailoring outreach for hard-to-reach populations - The role of caregiver support in Alzheimer’s research 4. Key learnings in neuropsychiatry - The importance of compassion and continuity of care in patient retention - Educating communities on the value of memory assessments and clinical trials What’s your take on advancing Alzheimer’s research through tech and patient-centered recruitment? 👇Listen to the full episode in the comments!

How do you progress a psychedelic-based treatment through development and onto patients in need? That's what our Founder and CEO, Cosmo Feilding Mellen, discussed with Brandon Li on the 'Power to the Patients' podcast, where he covered everything from why shorter treatment duration matters to ethics in psychedelic medicines. Full episode in the comments.

Trying something new: here's a recap of my recent Podcast episode with Cosmo Feilding Mellen, CEO of Beckley Psytech Beckley is doing interesting work on 5-MEO-DMT for Treatment Resistant Depression, a 1hr psychedelic experience instead of 4-10hrs